Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageDebt RatioDebt to EquityEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Equity

Inhibikase Therapeutics (IKT) EBITDA Margin (2020 - 2023)

Historic EBITDA Margin for Inhibikase Therapeutics (IKT) over the last 4 years, with Q4 2023 value amounting to 440356600.0%.

  • Inhibikase Therapeutics' EBITDA Margin fell 4403497803600.0% to 440356600.0% in Q4 2023 from the same period last year, while for Sep 2024 it was 2006393700.0%, marking a year-over-year decrease of 20063876552300.0%. This contributed to the annual value of 7711.98% for FY2023, which is 69741900.0% up from last year.
  • As of Q4 2023, Inhibikase Therapeutics' EBITDA Margin stood at 440356600.0%, which was down 4403497803600.0% from 5773.14% recorded in Q3 2023.
  • In the past 5 years, Inhibikase Therapeutics' EBITDA Margin ranged from a high of 186.56% in Q1 2021 and a low of 440356600.0% during Q4 2023
  • Over the past 4 years, Inhibikase Therapeutics' median EBITDA Margin value was 5440.26% (recorded in 2023), while the average stood at 27549232.05%.
  • In the last 5 years, Inhibikase Therapeutics' EBITDA Margin skyrocketed by 2000000000bps in 2022 and then tumbled by 2000000000bps in 2023.
  • Inhibikase Therapeutics' EBITDA Margin (Quarter) stood at 704.66% in 2020, then plummeted by -36703bps to 259334.41% in 2021, then skyrocketed by 97bps to 6819.64% in 2022, then crashed by -6457080bps to 440356600.0% in 2023.
  • Its EBITDA Margin was 440356600.0% in Q4 2023, compared to 5773.14% in Q3 2023 and 5107.38% in Q2 2023.